Screener
Dianthus Therapeutics DNTH Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Property and equipment, net | 274 | 296 |
| Right-of-use operating lease assets | 1,293 | 1,337 |
| Other assets and restricted cash | 11,538 | 9,716 |
| Total assets | $1,246,884 | $530,922 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,274 | $9,725 |
| Accrued expenses | 31,125 | 19,452 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's total assets?
- Dianthus Therapeutics (DNTH) reported total assets of $1.25B in Q1 2026.
- How has Dianthus Therapeutics's total assets changed year-over-year?
- Dianthus Therapeutics's total assets increased by 257.7% year-over-year, from $348.58M to $1.25B.
- What is the long-term trend for Dianthus Therapeutics's total assets?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's total assets has grown at a 26.9% compound annual growth rate (CAGR), from $161.62M to $530.92M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Dianthus Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude